Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies

Clinical Cancer Research

Volumn 11, Issue 18, 2005, Pages 6615-6624

  Yee, Karen W L ^a   Hagey, Anne ^b   Verstovsek, Srdan ^a   Cortes, Jorge ^a   Garcia Manero, Guillermo ^a   O'Brien, Susan M ^a   Faderl, Stefan ^a   Thomas, Deborah ^a   Wierda, William ^a   Kornblau, Steven ^a   Ferrajoli, Alessandra ^a   Albitar, Maher ^a   McKeegan, Evelyn ^b   Grimm, David R ^b   Mueller, Toby ^b   Holley Shanks, Rhonda R ^b   Sahelijo, Leonardo ^b   Gordon, Gary B ^b   Kantarjian, Hagop M ^a   Giles, Francis J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALANYLTHREONINE; ANTIMITOTIC AGENT; BETA TUBULIN; COLCHICINE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; THREONINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; AGED; ANOREXIA; ARTICLE; BLAST CELL; BODY WEIGHT DISORDER; BONE PAIN; CANCER RECURRENCE; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CIRCULATING ENDOTHELIAL CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY SKIN; DYSPHAGIA; ENDOTHELIUM CELL; FATIGUE; FEMALE; GENE; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; ILEUS; INTESTINE OBSTRUCTION; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MICROTUBULE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; THROMBOCYTE COUNT; TUBB GENE; WEIGHT REDUCTION;

ACUTE DISEASE; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD146; ANTIGENS, CD31; ANTIGENS, CD45; ANTINEOPLASTIC AGENTS; CONSTIPATION; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; FEMALE; GLYCOPROTEINS; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; MALE; MICROTUBULES; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NAUSEA; NEOPLASM CIRCULATING CELLS; NEOPLASM RECURRENCE, LOCAL; NEURAL CELL ADHESION MOLECULES; PEPTIDES; SULFONAMIDES; TREATMENT OUTCOME; TUBULIN; VOMITING;

EID: 25144483821     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0650     Document Type: Article

References (62)

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
2. Rowinsky EK. Current developments in antitumor antibiotics, epipodophyllotoxins, and Vinca alkaloids. Curr Opin Oncol 1991;3:1060-9.
3. Distefano M, Scambia G, Ferlini C, et al. Antiproliferative activity of a new class of taxones (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer 1997;72:844-50.
4. Staretz ME, Hastie SB. Synthesis and tubulin binding of novel C-10 analogues of colchicine. J Med Chem 1993;36:758-64.
5. Rowinsky EK, Long GS, Noe DA, et al. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin Cancer Res 1997;3:401-7.
6. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002;83:21-38.
7. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-25.
8. Iwamoto Y, Nishio K, Fukumoto H, Yoshimatsu K, Yamakido M, Saijo N. Preferential binding of E7010 to murine β 3-tubulin and decreased β 3-tubulin in E7010-resistant cell lines. Jpn J Cancer Res 1998; 89:954-62.
9. Li Q, Sham HL. Discovery and development of antimitotic agents that inhibit tubulin polymerization for the treatment of cancer. Expert Opin Ther Patents 2002;12:1663-702.
10. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57:3208-13.
11. Yamamoto K, Noda K, Yoshimura A, Fukuoka M, Furuse K, Niitani H. Phase I study of E7010. Cancer Chemother Pharmacol 1998;42:127-34.
12. Abbott Laboratories. Investigator's brochure, edition no. 3.1. January 7, 2004.
13. Gwaltney SL II, Imade HM, Li Q, et al. Novel sulfonate derivatives: potent antimitotic agents. Bioorg Med Chem Lett 2001;11:1671-3.
14. Yoshino H, Ueda N, Niijima J, et al. Novel sulfonamides as potential, systematically active antitumor agents. J Med Chem 1992;35:2496-7.
15. Segreti JA, Polakowski JS, Koch KA, et al. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 2004;54:273-81.
16. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991;27:482-7.
17. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to soild tumour therapy: evaluation of tubulin binding agents. Br J Cancer Suppl 1996;27:586-8.
18. Hill SA, Sampson LE, Chaplin DJ. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 1995;63:119-23.
19. Nihei Y, Suzuki M, Okano A, et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 1999;90:1387-95.
20. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-72.
21. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
22. Petrangolini G, Cassinelli G, Pratesi G, et al. Antitumor and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft. Br J Cancer 2004;90:1464-8.
23. Cassinelli G, Lanzi C, Supino R, etal. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer. Clin Cancer Res 2002;8:2647-54.
24. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-5.
25. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95:309-13.
26. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637-44.
27. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717-21.
28. Aguayo A, Kantarjian HM, Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002;95:1923-30.
29. Kuzu I, Beksac M, Aral M, Celebi H, Elhan AH, Erekul S. Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymphoma 2004;45:1185-90.
30. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001;86:23-33.
31. Rimsza LM, Ahrens KP, Massey JK, Pastos KM, Mainwaring MG, Braylan RC. AML, angiogenesis, and prognostic variables. Blood 2002;100:1517-8.
32. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-61.
33. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964-72.
34. O'Reilly M. The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs 1997;15:5-13.
35. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-8.
36. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997;337:1584-90.
37. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003;361:206-10.
38. Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am J Hematol 2002;70:100-6.
39. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoetic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-201.
40. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-7.
41. + cells identifies a population of functional endothelial precursors. Blood 2000;95:952-8.
42. Kobayashi H, Hande KR, Berlin JD, et al. Phase I results of ABT-751, a novel microtubulin inhibitor, administered daily × 7 every 3 weeks, [abstract 2079]. Proc Am Soc Clin Oncol 2004;23:146.
43. Sprague E, Fleming GF, Carr R, et al. Phase I study of 21-day continuous dosing of the oral antimitotic agent ABT-751. [abstract 518]. Proc Am Soc Clin Oncol 2003;22:129.
44. CTEP, National Cancer Institute: Common Toxicity Criteria Manual, Version 2.0. Bethesda (MD): National Cancer Institute: 1999. pp. 1-35.
45. Nogales E, Wolf SG, Downing KH. Structure of the αβ tubulin dimer by electron crystallography. Nature 1998;391:199-203.
46. Erratum in: Nature 1938;393:191.
47. Uppuluri S, Knipling L, Sackett DL, Wolff J. Localization of the colchicine-binding site of tubulin. Proc Natl Acad Sci U S A 1993;90:11598-602.
48. Serrieman HK, Lind MJ, Cawkell L. Do β-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004;5:158-64.
49. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations. J Clin Oncol 1999;17:1786-93.
50. Kelley MJ, Li S, Harpole DH. Genetic analysis of the β-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst 2001;93:1886-8.
51. Sale S, Oefner PJ, Sikic BI. Genetic analysis of the β-tubulin gene, TUBB, in non-small cell lung cancer. J Natl Cancer Inst 2002;94:776-7.
52. Monzó M, Taron M, Rosell R. Genetic analysis of the β-tubulin gene,TUBB, in non-small cell lung cancer. J Natl Cancer Inst 2002;94:774-6.
53. National Center for Biotechnology Information. LocusLink: TUBB2 - tubulin, β 2. http://www.ncbi. nlm.nih.gov/LocusLink/LocRpt.cgi?I = 7280. Accessed January 31, 2005.
54. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;61:4341-4.
55. Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002;359:2078-83.
56. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
57. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3 -kinase/Akt pathway. J Clin Invest 2001;108:391-7.
58. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001;108:399-405.
59. Woywodt A, Schroeder M, Mengel M, et al. Circulating endothelial cells are a novel marker of cyclosporine-induced endothelial damage. Hypertension 2003;41:720-3.
60. Woywodt A, Scheer J, Hambach L, et al. Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood 2004;103:3603-5.
61. Woywodt A, Haubitz M, Buchholz S, Hertenstein B. Counting the cost: markers of endothelial damage in hematopoietic stem cell transplantation. Bone Marrow Transplant 2004;34:1015-23.
62. Mutunga M, Fulton B, Bullock R, et al. Circulating endothelial cells in patients with septic shock. Am J Respir Crit Care Med 2001;163:195-200.